The restructuring includes a reorganization of resources and a reduction in the work force to reflect significant changes in the Philippine market and in its product mix. Henceforth, Pharmalink, a division of Zuellig Pharma Inc. will market the retail products Axid, Ceclor, Dobutrex, Ilosene, Keflex, Tapazole and Vancocin.
"This restructuring is designed to focus the right amount of resources on our existing and new specialty product opportunities," said Sandeep Gupta, general manager of Eli Lilly Phils. Lilly’s product portfolio will now focus on gemcitabine (Gemzar), recombinant human insulin (Humulin), olanzapine (Zyprexa), raloxifene (Evista) and tadalafil (Cialis).
Gupta added, "we are very pleased with the expanded relationship with Pharmalink for our retail products. This will allow us to optimize the opportunity, and continue to sell these products in the Philippine marketplace without interruption."
Lilly has been in the Philippines since 1961. "We are confident that these changes will strengthen our organization so we can continue to be successful for the next 40 years in the Philippines," said Richard A. Smith, president of Asian Operations Region for Eli Lilly."